In addition to new products such as Medtronic’s Amplify, which combines collagen and ceramic matrix designed for implantation in single-level posterolateral lumbar fusions, next year’s bone graft substitute market will include technology from BioMimetic Therapeutics, a platelet-derived growth factor. Additional products, such as NuVasive’s Osteocel Plus, Orthofix’s Trinity Evolution and AlloSource’s AlloStem will continue to utilize stem cell technology to promote issue cell growth and bone healing.
MRG’s US Markets for Orthopedic Biomaterials 2010 report includes trends for fuel product adoption and market growth for graft substitutes, cell concentration systems and knee cartilage repair.
Read the Millennium Research Group’s release on the bone graft substitute market.
Read other coverage on bone graft substitutes:
– FDA Clears Osteoinductive Bone Graft Substitute From Wright Medical Group
– Etex’s EquivaBone bone Graft Substitute Wins FDA Clearance for More Uses
– FDA Panel Votes to Recommend Approval for Medtronic’s Amplify Spine Device
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
